Monitoring of Adverse Event for Anticancer Drugs Using Mobile Healthcare
Not Applicable
- Conditions
- Cancers
- Registration Number
- JPRN-UMIN000052672
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients who have received no anticancer therapy but only supportive or palliative therapy 2. patients with a prognosis predicted to be less than 6 months
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Detection rate of adverse events of anticancer therapy by mobile healthcare
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie adverse events in anticancer drug monitoring via mobile healthcare?
How does mobile healthcare compare to traditional methods in tracking adverse events for cancer therapies?
Are there specific biomarkers that correlate with adverse event severity in cancer patients using mobile monitoring?
What are the most common adverse events associated with anticancer drugs in observational cancer trials?
How can mobile healthcare platforms improve adverse event management in cancer treatment protocols?